Table 4.
FDA-approved gonadotropin-releasing hormone (GnRH) peptides.
| Peptide (Trade Name) | Indication | Therapeutic Target | Route | FDA Approval Year |
|---|---|---|---|---|
| Agonists | ||||
| Goserelin (Zoladex) | Managing carcinoma of the prostate, addressing endometriosis, and providing palliative treatment for advanced breast cancer | GnRH | SC | 1989 |
| Leuprolide (Lupron) | Palliative treatment for prostate cancer, uterine leiomyomata, endometriosis, and central precocious puberty | GnRH | IM | 1995 |
| Nafarelin (Synarel) | To address endometriosis, including the alleviation of pain and the reduction of endometriotic lesions | GnRH | Nasal solution | 1998 |
| Trelstar (triptorelin) | Palliative treatment of advanced prostate cancer | GnRH | IM | 2000 |
| Histrelin (Supprelin LA) | Treatment of central precocious puberty (CPP) in children | GnRH | SC | 2007 |
| GnRH | ||||
| Antagonists | ||||
| Ganirelix (Antagon) | A fertility medication designed to prevent premature LH surges or ovulation in women undergoing fertility treatment with controlled ovarian hyperstimulation | GnRH | SC | 1999 |
| Cetrorelix (Cetrotide) | To inhibit premature ovulation | GnRH | SC | 2000 |
| Abarelix (Plenaxis) | Palliative treatment of advanced prostate cancer | GnRH | IM | 2003 |
| Degarelix (Firmagon) | Advanced prostate cancer | GnRH | SC | 2008 |
GnRH, gonadotropin-releasing hormone; IM, intramuscular; LH, luteinizing hormone; SC, subcutaneous.